How does cosentyx improve patient conditions long term?

How does Cosentyx maintain results over time?

Cosentyx works by blocking interleukin-17A, a protein that drives inflammation in skin, joints, and the spine. This blockade keeps inflammatory signaling low, so skin plaques stay flat and joint pain and swelling remain reduced for months to years in many patients. Studies show that roughly three-quarters of psoriasis patients keep their skin mostly or completely clear at five years with continued treatment.

What happens when treatment stops?

Most patients see symptoms return within months after stopping Cosentyx. Skin plaques and joint pain reappear as interleukin-17A activity resumes. Data indicate that the majority of patients who abate treatment lose their response by six months, so continuous therapy keeps the lang-term gains intact.

How does Cosentyx compare with other biologics?

Cosentyx shows comparable long-term skin clearance rates to Humira and Taltz. Cosentyx also maintains joint improvement in psoriatic arthritis at rates similar to Tremfya and Skyrizi. In ankylosing spondylitis, Cosentyx keeps pain and stiffness low for five years, while some competitors have only four-year data. The choice between agents largely depends on patient comorbidities and previous treatment responses.

Why are companies challenging Cosentyx patents?

Multiple generic manufacturers have filed challenges against Cosentyx-related patents. Companies seek early entry into the market once core patents expire. The earliest reported date for biosimilar entry is 2025 in Europe and 2026 in the U.S., but litigation may delay arrival until 2028 or later.

When does Cosentyx exclusivity expire?

Core U.S. patents expire in 2026. Core European patents expire in 2025. [1]

When does Cosentyx patent expire?